tirzepatide is fda approved approves weight-loss drug Zepbound to treat sleep apnea – San Diego Union-Tribune FDA approves Lilly's Mounjaro™ (tirzepatide)

Type 2 Diabetes and Metabolic Health Glutathione deficiency is commonly observed in type 2 diabetes, driven by hyperglycemia-induced oxidative stress, impaired cysteine availability, and reduced activity of glutathione synthesis enzymes [2][11]

Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 Personal or family history of thyroid cancer Personal history of Suicidal thoughts or suicide attempts Personal history of Diabetic Retinopathy Personal history of Pancreatitis or gall bladder issues Currently pregnant or actively trying to get pregnant Known serious hypersensitivity to tirzepatide or any of the excipients in Zepbound Common side effects The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn

Tirzepatide and semaglutide shared similar rates for nausea, diarrhea, abdominal pain, and dyspepsia , but semaglutide had higher rates of vomiting, constipation, and GERD

Medications are initiated at low doses and gradually increased over several weeks to minimise gastrointestinal side effects such as nausea and vomiting

fast forward to 2022 and that number quintupled to ~$8.5B

healio.com 2Stanford Medicine (July 2026)